A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice
Tóm tắt
Recent development in the field of COPD has focused on strategies aimed at reducing the underlying inflammation through selective inhibition of the phosphodiesterase type IV (PDE4) isoform. Although the anti-inflammatory and bronchodilator activity of selective PDE4 inhibitors has been well documented, their low therapeutic ratio and dose-dependent systemic side effects have limited their clinical utility. This study examined the effect of 2'-deoxy-2'-Fluoro-β-D-Arabinonucleic Acid (FANA)-containing antisense oligonucleotides (AON) targeting the mRNA for the PDE4B/4D and 7A subtypes on lung inflammatory markers, both in vitro and in vivo. Normal human bronchial epithelial (NHBE) cells were transfected with FANA AON against PDE4B/4D and 7A alone or in combination. mRNA levels for target PDE subtypes, as well as secretion of pro-inflammatory chemokines were then measured following cell stimulation. Mice were treated with combined PDE4B/4D and 7A AON via endo-tracheal delivery, or with roflumilast via oral delivery, and exposed to cigarette smoke for one week. Target mRNA inhibition, as well as influx of inflammatory cells and mediators were measured in lung lavages. A two-week smoke exposure protocol was also used to test the longer term potency of PDE4B/4D and 7A AONs. In NHBE cells, PDE4B/4D and 7A AONs dose-dependently and specifically inhibited expression of their respective target mRNA. When used in combination, PDE4B/4D and 7A AONs significantly abrogated the cytokine-induced secretion of IL-8 and MCP-1 to near baseline levels. In mice treated with combined PDE4B/4D and 7A AONs and exposed to cigarette smoke, significant protection against the smoke-induced recruitment of neutrophils and production of KC and pro-MMP-9 was obtained, which was correlated with inhibition of target mRNA in cells from lung lavages. In this model, PDE AONs exerted more potent and broader anti-inflammatory effects against smoke-induced lung inflammation than roflumilast. Moreover, the protective effect of PDE4B/4D and 7A AON was maintained when a once-weekly treatment schedule was used. These results indicate that inhaled AON against PDE4B/4D and 7A have unique effects on biomarkers that are believed to be important in the pathophysiology of COPD, which supports further development as a potential therapy in this disease.
Tài liệu tham khảo
Kim V, Rogers TJ, Criner GJ: New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5:478–485.
Barnes PJ: Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008, 8:183–192.
Chung KF, Adcock IM: Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008, 31:1334–1356.
Pelkonen : Smoking: relationship to chronic bronchitis, chronic obstructive pulmonary disease and mortality. Curr Opin Pulm Med. 2008,14(2):105–109.
Mannino DM, Buist AS: Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370:765–773.
O'Donnell R, Breen D, Wilson S, Djukanovic R: Inflammatory cells in the airways in COPD. Thorax 2006, 61:448–454.
Cowburn AS, Condliffe AM, Farahi N, Summers C, Chilvers ER: Advances in neutrophil biology: clinical implications. Chest 2008, 134:606–612.
Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, Donner CF: Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998, 12:380–386.
Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, Mapp CE, Fabbri LM, Donner CF, Saetta M: Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998, 158:1277–1285.
Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF: Increased Activity of Matrix Metalloproteinase-8 and Matrix Metalloproteinase-9 in Induced Sputum From Patients With COPD. Chest 2004, 126:1802–1810.
Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A: Neutrophil Elastase Contributes to Cigarette Smoke-Induced Emphysema in Mice. Am J Pathol. 2003,163(6):2329–2335.
Churg A, Zay K, Shay S, Xie C, Shapiro SD, Hendricks R, Wright JL: Acute Cigarette Smoke-Induced Connective Tissue Breakdown Requires both Neutrophils and Macrophage Metalloelastase in Mice. Am J Respir Cell Mol Biol. 2002,27(3):368–374.
Peleman RARP, Kips JC, Joos GF, Pauwels RA: The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999, 13:839–843.
Keatings VM, Collins PD, Scott DM, Barnes PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996, 153:530–534.
Schulz CWK, Harth M, Krätzel K, Kunz-Schughart L, Pfeifer M: Expression and release of interleukin-8 by human bronchial epithelial cells from patients with chronic obstructive pulmonary disease, smokers, and never-smokers. Respiration 2003, 70:254–261.
Traves SLCS, Russell RE, Barnes PJ, Donnelly LE: Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002, 57:590–595.
Torphy TJ: Phosphodiesterase Isozymes: Molecular Targets for Novel Antiasthma Agents. Am J Respir Crit Care Med. 1998,157(2):351–370.
Conti M, Jin SL: The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 1999, 63:1–38.
Jin SLC, Lan L, Zoudilova M, Conti M: Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages. J Immunol. 2005,175(3):1523–1531.
Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, Jin SL, Conti M: Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation. J Immunol. 2004,173(12):7531–7538.
Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G: Roflumilast Fully Prevents Emphysema in Mice Chronically Exposed to Cigarette Smoke. Am J Respir Crit Care Med 2005, 172:848–853.
Kuss H, Hoefgen N, Johanssen S, Kronbach TCR: In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12–281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 2003, 307:373–385.
Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001,297(1):280–290.
Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD: Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366:563–571.
Giembycz MA: An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol 2006, 62:138–152.
Rennard SI, Schachter N, Strek M, Rickard K, Amit O: Cilomilast for COPD: Results of a 6-Month, Placebo-Controlled Study of a Potent, Selective Inhibitor of Phosphodiesterase 4. Chest 2006, 129:56–66.
Fan Chung K: Phosphodiesterase inhibitors in airways disease. European Journal of Pharmacology 2006, 533:110–117.
Dietsch GN, DiPalma CR, Eyre RJ, Pham TQ, Poole KM, Pefaur NB, Welch WD, Trueblood E, Kerns WD, Kanaly ST: Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity. Toxicologic Pathology 2006, 34:39–51.
Losco PEEE, Barat SA, Blackshear PE, Reyderman L, Fine JS, Bober LA, Anthes JC, Mirro EJ, Cuss FM: The toxicity of SCH 35 a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol Pathol 1591, 32:295–308.
Chapman RW, House A, Jones H, Richard J, Celly C, Prelusky D, Ting P, Hunter JC, Lamca J, Phillips JE: Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats. Eur J Pharmacol 2007, 571:215–221.
Barnes PJ: Frontrunners in novel pharmacotherapy of COPD. Curr Opin Pharmacol 2008, 8:300–307.
Barnes PJ: Emerging pharmacotherapies for COPD. Chest 2008, 134:1278–1286.
Robichaud A, Stamatiou PB, Jin C, Lachance N, MacDonald D, Laliberté F, Liu S, Huang C, Conti M, Chan CC: Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002, 110:1045–1052.
Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C: Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D. J Immunol. 2007,178(8):4820–4831.
Vijayakrishnan L, Rudra S, Eapen MS, Dastidar S, Ray A: Small-molecule inhibitors of PDE-IV and -VII in the treatment of respiratory diseases and chronic inflammation. Expert Opinion on Investigational Drugs 2007, 16:1585–1599.
Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, Giembycz MA: Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol. 2003,284(2):L279-L289.
Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA: Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes. Mol Pharmacol 2004, 66:1679–1689.
Karras JG, Crosby JR, Guha M, Tung D, Miller DA, Gaarde WA, Geary RS, Monia BP, Gregory SA: Anti-Inflammatory Activity of Inhaled IL-4 Receptor-{alpha} Antisense Oligonucleotide in Mice. Am J Respir Cell Mol Biol 2007, 36:276–285.
Crosby JR, Guha M, Tung D, Miller DA, Bender B, Condon TP, York-DeFalco C, Geary RS, Monia BP, Karras JG, Gregory SA: Inhaled CD86 Antisense Oligonucleotide Suppresses Pulmonary Inflammation and Airway Hyper-responsiveness in Allergic Mice. J Pharmacol Exp Ther 2007, 321:938–946.
Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG, Wong WS: Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 2005, 171:571–578.
Crooke ST: Progress in Antisense Technology. Annual Review of Medicine 2004, 55:61–95.
Sahu NK, Shilakari G, Nayak A, Kohli DV: Antisense technology: a selective tool for gene expression regulation and gene targeting. Curr Pharm Biotechnol 2007, 8:291–304.
Bhindi R, Fahmy RG, Lowe HC, Chesterman CN, Dass CR, Cairns MJ, Saravolac EG, Sun L-Q, Khachigian LM: Brothers in Arms: DNA Enzymes, Short Interfering RNA, and the Emerging Wave of Small-Molecule Nucleic Acid-Based Gene-Silencing Strategies. Am J Pathol 2007, 171:1079–1088.
Tanaka M, Nyce J: Respirable antisense oligonucleotides: a new drug class for respiratory disease. Respiratory Research 2001, 2:5–9.
Ball H, Sandrasagra A, Tang L, Van Scott M, Wild J, Nyce J: Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma. Am J Pharmacogenomics 2003, 3:97–106.
Guimond A, Viau E, Aube P, Renzi PM, Paquet L, Ferrari N: Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates. Pulm Pharmacol Ther 2008, 21:845–854.
Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, Davis B, Strinich T, Howie K, Duong M, Watson RM, Renzi PM, O'Byrne PM: Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177:952–958.
Damha MJ, Noronha AM, Wilds CJ, Trempe JF, Denisov A, Gehring K, Pon RT: Properties of arabinonucleic acids (ANA & 20'F-ANA): implications for the design of antisense therapeutics that invoke RNase H cleavage of RNA. Nucleosides Nucleotides Nucleic Acids 2001, 20:429–440.
Ferrari N, Bergeron D, Tedeschi A-L, Mangos MM, Paquet L, Renzi PM, Damha MJ: Characterization of Antisense Oligonucleotides Comprising 2'-Deoxy-2'-Fluoro-beta-D-Arabinonucleic Acid (FANA): Specificity, Potency, and Duration of Activity. Ann NY Acad Sci 2006, 1082:91–102.
Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL: Tumor Necrosis Factor-{alpha} Drives 70% of Cigarette Smoke-induced Emphysema in the Mouse. Am J Respir Crit Care Med 2004, 170:492–498.
Churg A, Cosio M, Wright JL: Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol 2008, 294:L612–631.
Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121–127.
Allakhverdi Z, Allam M, Guimond A, Ferrari N, Zemzoumi K, Seguin R, Paquet L, Renzi PM: Multitargeted Approach Using Antisense Oligonucleotides for the Treatment of Asthma. Ann NY Acad Sci 2006, 1082:62–73.
Allakhverdi Z, Allam M, Renzi PM: Inhibition of Antigen-induced Eosinophilia and Airway Hyperresponsiveness by Antisense Oligonucleotides Directed against the Common beta Chain of IL-3, IL-5, GM-CSF Receptors in a Rat Model of Allergic Asthma. Am J Respir Crit Care Med. 2002,165(7):1015–1021.
Fortin M, Ferrari N, Higgins M-E, Seguin S, Allam M, Allakhverdi Z, Piaget-Rodriguez C, Paquet L, Renzi PM: Effects of Antisense Oligodeoxynucleotides Targeting CCR3 on the Airway Response to Antigen in Rats. Oligonucleotides 2006, 16:203–212.